Oncology drug developer Chordia Therapeutics has raised series A funding from backers including Takeda, from which it is licensing its preclinical drugs.

Japan-based pharmaceutical firm Takeda has invested an undisclosed amount in Chordia Therapeutics, a oncology drug development spinout, as part of its series A round, Fierce Biotech reported yesterday.

Although the round’s size has not been disclosed, it also includes Mitsubishi UFJ Capital and SMBC Venture Capital, the venture capital arms of banks Mitsubishi UFJ Financial Group and Sumitomo Mitsui Banking Corporation, as well as Kyoto University Innovation Capital.

Chordia was formed by six former scientists at Takeda and has licensed…